TWiV 945: Clinical update with Dr. Daniel Griffin

October 15, 2022

In his weekly clinical update Dr. Griffin discusses a healthcare-associated infection with Monkeypox virus, air and surface sampling for monkeypox virus in a UK hospital, misrepresentation and nonadherence regarding COVID19 public health measures, tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine, clinical, virologic, and immunologic evaluation of symptomatic rebound following Nirmatrelvir/Ritonavir treatment, early outpatient treatment with Eemdesivir in patients at high risk for severe COVID-19, Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes, and outcomes among confirmed cases and a matched comparison group in the long-COVID in Scotland.

Click arrow to play
Download TWiV 945 (27 MB .mp3, 44 min)
Subscribe (free): Apple PodcastsGoogle PodcastsRSSemail

Become a patron of TWiV!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to

Leave a Reply

Your email address will not be published. Required fields are marked *

One comment on “TWiV 945: Clinical update with Dr. Daniel Griffin

  1. Ebony Gary Oct 15, 2022

    Interesting results from chAdox intranasal trial! Lots of preclinical work on ways to drive mucosal immunity to vaccines with chemokine direction either by prime and pull (Iwasaki, many-HSV) or by parenteral delivery of chemokine adjuvant (Gary et al. Cell reports med. 2023- SARS2). Very exciting work, not just got COVID vaccines but vaccines for any mucosal pathogen.